GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Caplin Point Laboratories Ltd (BOM:524742) » Definitions » Revenue

Caplin Point Laboratories (BOM:524742) Revenue : ₹16,941 Mil (TTM As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Caplin Point Laboratories Revenue?

Caplin Point Laboratories's revenue for the three months ended in Mar. 2024 was ₹4,532 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₹16,941 Mil. Caplin Point Laboratories's Revenue per Share for the three months ended in Mar. 2024 was ₹59.68. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ₹222.58.

Good Sign:

Caplin Point Laboratories Ltd has shown predictable revenue and earnings growth.

During the past 12 months, the average Revenue per Share Growth Rate of Caplin Point Laboratories was 15.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 17.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 20.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was 26.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Caplin Point Laboratories's highest 3-Year average Revenue per Share Growth Rate was 39.30% per year. The lowest was 9.30% per year. And the median was 26.35% per year.


Caplin Point Laboratories Revenue Historical Data

The historical data trend for Caplin Point Laboratories's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caplin Point Laboratories Revenue Chart

Caplin Point Laboratories Annual Data
Trend Jun15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,445.18 10,482.60 12,694.10 14,667.30 16,941.00

Caplin Point Laboratories Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,892.80 3,953.20 4,100.60 4,355.00 4,532.20

Competitive Comparison of Caplin Point Laboratories's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caplin Point Laboratories's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's Revenue distribution charts can be found below:

* The bar in red indicates where Caplin Point Laboratories's Revenue falls into.



Caplin Point Laboratories Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹16,941 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Caplin Point Laboratories  (BOM:524742) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Caplin Point Laboratories Revenue Related Terms

Thank you for viewing the detailed overview of Caplin Point Laboratories's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Caplin Point Laboratories (BOM:524742) Business Description

Traded in Other Exchanges
Address
Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096
Caplin Point Laboratories Ltd is the India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, liquid orals, dry powder, soft gels, penems injections, suppositories. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops. The business of the company is organized into the following product segments, Antibiotics, Nsaids, Ophthalmics, Pain Management, and Antiulcers. Its products have a presence in the Latin American and African markets.

Caplin Point Laboratories (BOM:524742) Headlines

No Headlines